Understand the source comparison
Comparison: SLU-PP-332 vs Other ERR Modulators
SLU-PP-332 0.4 µM <5% at 10 µM 2.8–3.5× in skeletal muscle Metabolic disease models, mitochondrial dysfunction studies Selective ERRα/γ agonist. No TRβ binding at therapeutic doses GSK4716 1.0 µM (ERRγ-selective) ~30% at 10 µM 1.8–2.2× (confounded by thyroid e
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- SLU-PP-332
- 0.4 µM
- <5% at 10 µM
- 2.8–3.5× in skeletal muscle
- Metabolic disease models, mitochondrial dysfunction studies
- Selective ERRα/γ agonist. No TRβ binding at therapeutic doses
- GSK4716
- 1.0 µM (ERRγ-selective)
- ~30% at 10 µM
- 1.8–2.2× (confounded by thyroid effects)
- Early-phase ERR biology studies
- First synthetic ERR agonist. Limited selectivity
- XCT790
- 5.1 µM (ERRα inverse agonist)
- Minimal
- N/A (inverse agonist. Suppresses activity)
- ERRα knockdown models
- Used to block ERRα, not activate it
- DY131 (ERRγ agonist)
- 0.6 µM (ERRγ-selective)
- <10% at 5 µM
- 1.5–2.0× (primarily in BAT)
- Brown adipose tissue thermogenesis studies
- ERRγ-selective. Less relevant for muscle